Tirzepatide When Pregnant: The Honest Clinical Picture

Step one: stop the medicine and tell your clinical team today

The moment a positive pregnancy test appears, tirzepatide stops. That is the consistent instruction across the Summary of Product Characteristics, NHS guidance, and clinical practice. The medicine has a half-life of roughly five days, so it does not clear the body in hours, another reason early action matters. Your GP and, if you are using a private service, your prescribing pharmacist both need to know.

If tirzepatide is still in the fridge door from your last order, it should not be used. Contact your prescriber before doing anything else. Reaching our team takes a few minutes if you're a nume patient, aftercare is available seven days a week specifically for situations like this.

You do not need to feel alarmed by an accidental exposure before you knew you were pregnant. If you want a fuller picture of what being pregnant on tirzepatide means in practice, including what early exposure looks like from a clinical perspective, that is covered in detail on a dedicated page. That said, your midwife and obstetric team should be made aware so they can factor it into your care.

Step two: understand what the evidence actually shows

The honest answer is that the evidence base in pregnant humans is thin. Tirzepatide was not tested in clinical trials involving pregnant women, this is standard practice for new medicines during development. What exists comes from animal reproductive studies, and those findings were concerning enough that the medicine's licence excludes pregnancy entirely. In rat studies, tirzepatide caused reduced foetal weight and skeletal abnormalities at doses below the human therapeutic range. Whether those findings translate to human pregnancies is unknown, but the risk profile cannot be called negligible on the available data.

The NHS medicines page for tirzepatide is explicit: do not take tirzepatide if you are pregnant. For a closer look at Mounjaro when pregnant, including what the SmPC and clinical guidance say about washout periods and contraception, that page sets out the details your prescriber will be working from. The SmPC recommends that women use effective contraception during treatment and for a defined washout period before attempting to conceive, the exact duration should be confirmed with your prescriber rather than inferred from general reading.

A practical concern separate from direct foetal risk: tirzepatide reduces appetite significantly. Adequate nutrition, folate intake, and steady weight gain are all important in pregnancy. Active appetite suppression through a GLP-1 and GIP receptor agonist works directly against those goals.

Step three: plan what happens after the pregnancy

Breastfeeding is also in the not-recommended category. Whether tirzepatide passes into breast milk in meaningful quantities is not established in humans. In animal studies it was present in milk. Until robust data exists, the safe default is to avoid it while feeding.

Once pregnancy and breastfeeding have concluded, a conversation with a prescriber about resuming treatment (or choosing a different approach) is entirely reasonable. Weight management after pregnancy is a legitimate health priority. Our clinical team reviews each case individually rather than applying a blanket rule about timing; the clinical picture after delivery, including any gestational diabetes diagnosis or significant weight change, all feed into that assessment.

Patients who stopped tirzepatide mid-treatment sometimes ask whether they need to restart at the 2.5mg starter dose. That is a clinical decision, not a rule that can be answered here, it depends on how long the gap was, what dose you were taking, and your current health picture. Your prescriber will guide that conversation. For general context on how treatment works, the weight management treatment overview is a useful starting point.

Step four: get the contraception question right before resuming

This matters more than many patients realise. Women taking tirzepatide who rely on the oral contraceptive pill need to be aware that tirzepatide slows gastric emptying, which can reduce how reliably the pill is absorbed. NHS England's guidance on weight-management injections is specific: add a non-oral contraceptive method (condoms, for example) for the first four weeks of starting tirzepatide and for four weeks after every dose increase. This is distinct from semaglutide (Wegovy), where the same absorption concern has not been documented to the same degree.

If you are planning a future pregnancy and want to understand more about the relationship between tirzepatide and fertility, or what accidental pregnancy on tirzepatide typically means in practice, those questions are covered in dedicated pages. A common follow-on question is whether you can take Mounjaro when pregnant at all, and that page addresses the clinical reasoning behind the licence exclusion in plain terms. The core point stands regardless: contraception planning should be part of any tirzepatide consultation, and it is part of ours. Start with a free consultation with our prescribers when the time is right.